Who Will Pay for Tomorrow’s Medical Breakthroughs?

Ron Cohen, M.D., President and Chief Executive Officer, Acorda Therapeutics, Inc
Michael Rawlins, Chairman, National Institute of Health and Clinical Excellence
Ellen V. Sigal, Ph.D., Chair and Founder, Friends of Cancer Research
Reed Tuckson, M.D., Executive Vice President and Chief of Medical Affairs, UnitedHealth Group
Brook Byers, Partner, Kleiner Perkins Caufield & Byers
Margaret Anderson , Executive Director, FasterCures/The Center for Accelerating Medical Solutions

Even if we are successful at getting new treatments through the R&D and approval process, the question remains whether payors will be willing to pick up the tab for them. As the U.S. moves to significantly reduce healthcare costs, concern abounds that the scientific trajectory towards more personalized treatments will be squelched by the countervailing pressure to pay only for treatments deemed most effective in large populations of patients. What role are insurance coverage decisions – and insurers themselves – playing farther upstream in the R&D and investment process? Can patient groups bring harmony to the marriage of comparative effectiveness research and personalized medicine?

This entry was posted in Advocacy, Regenerative Medicine. Bookmark the permalink.